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Abstract
Conventional wisdom holds that only one of the two strands in a micro ribonucleic acid
(miRNA) precursor duplex is selected as the active miRNA guide strand. The complemen-
tary miRNA passenger strand, however, is thought to be inactive. High levels of the onco-
genic miRNA (oncomiR) guide strand called miR-17-5p is overexpressed in triple negative
breast cancer (TNBC) and can inhibit ribosomal translation of tumor suppressor gene
mRNAs, such as programmed cell death 4 (PDCD4) or phosphatase and tensin homolog
(PTEN). We hypothesized that knocking down the oncogenic microRNA (oncomiR) miR-17-
5p might restore the expression levels of PDCD4 and PTEN tumor suppressor proteins,
illustrating a route to oligonucleotide therapy of TNBC. Contrary to conventional wisdom,
antisense knockdown of oncomiR miR-17-5p guide strand reduced PDCD4 and PTEN pro-
teins by 1.8±0.3 fold in human TNBC cells instead of raising them. Bioinformatics analysis
and folding energy calculations revealed that mRNA targets of miR-17-5p guide strand,
such as PDCD4 and PTEN, could also be regulated by miR-17-3p passenger strand. Due to
high sequence homology between the antisense molecules and miR-17-3p passenger
strand, as well as the excess binding sites for the passenger strand on the 3’UTR of PDCD4
and PTENmRNAs, introducing a miR-17-3p DNA-LNAmimic to knock down miR-17-5p
reduced PDCD4 and PTEN protein expression instead of raising them. Our results imply
that therapeutic antisense sequences against miRNAs should be designed to target the
miRNA strand with the greatest number of putative binding sites in the target mRNAs, while
minimizing affinity for the minor strand.
Introduction
New cases of aggressive breast cancer are predicted to occur in 232,340 U.S. women in 2014,
and to kill 39,620 [1]. Triple-negative breast cancers (TNBC) lack estrogen receptor (ER), pro-
gesterone receptor (PR), and human epidermal growth factor receptor 2 (ErbB2, Her2), and
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represent 16% of cases (2). Without specific molecular targets, conventional chemotherapy of
TNBC yields modest clinical outcomes [2]. Thus, the 16% of breast cancer patients who suffer
from TNBC have worse prognoses than other subtypes of breast cancer [3] [2].
TNBC clearly needs newmolecular therapies that specifically target genes promoting cancer
cell survival. A variety of oncogenic micro ribonucleic acids (oncomiRs) are overexpressed in
TNBC, and are being studied intensively as targets for complementary oligonucleotide therapy [4].
OncomiRs are non-protein-coding RNAs of 18–25 nucleotides (nt) that form base pairs with spe-
cific sequences in mRNAs. They inhibit translation of mRNAs sterically or by inducing mRNA
degradation by Ago2 [5, 6]. Biogenesis of all miRNAs initiates in the nucleus, where primary miR-
NAs are transcribed by either RNA polymerase II or RNA polymerase III. Primary miRNA tran-
scripts are then processed by Drosha and its cofactor DGCR8 to produce shorter precursor
miRNA hairpins of ~70 nt [7]. Pre-miRNA hairpins are exported to the cytoplasm by exportin 5,
then cleaved by Dicer to yield double-stranded miRNAs. The guide strand of the double-stranded
miRNA is thought to exhibit weak hydrogen bonding at its 5’ end, favoring its binding to Ago2 in
an RNA-induced silencing complex (RISC), allowing the guide strand to be active against comple-
mentary mRNAs. The passenger strand is thought to be inactive, dissociated, and degraded [8].
Specific oncomiR target recognition is predominantly defined byWatson-Crick base pairing
that occurs between the seed region (nucleotide 2 to 8 from the 5’ end of the oncomiR guide
strand) and the 3’-untranslated regions (3’UTR) of target mRNAs. Translational repression by
oncomiRs can be achieved by perfect complementarity between oncomiRs and the 3’UTR of
mRNAs mediated by RISC, leading to mRNA degradation. Alternately, the translation of
mRNA is sterically inhibited through imperfect oncomiR-mRNA recognition [9]. On average,
each oncomiR has hundreds of possible mRNA targets [10]. As a result, complementary oligo-
nucleotide therapy against one oncomiR could impact a broad panel of genes.
The miR-17~92 cluster is one of the most studied of the oncomiR groups that play impor-
tant roles in cancer development. miRNAs from this cluster are generally up-regulated in vari-
ous cancers, including breast, lung, colon, pancreas, prostate, and gastric cancer [11, 12].
Caloric restriction (CR) and ionizing radiation (IR) down-regulate members of the miR-17~92
cluster in TNBC models, decreasing their metastatic activities by suppressing extracellular
matrix (ECM) mRNAs that exhibit miR-17-5p binding sites [13]. Among the seven members
of the miR-17~92 cluster, the guide strand miR-17-5p is predominantly responsible for pro-
moting migration and invasion of metastatic cancer cells, targeting the mRNAs of tumor sup-
pressor genes, such as PDCD4 (programmed cell death 4) and PTEN (phosphatase and tensin
homolog) [14]. Thus, miR-17-5p is considered to be an oncogenic miRNA, or oncomiR. The
tumor suppressor proteins PDCD4 and PTEN are usually depressed in TNBC, associated with
elevated oncomiR levels [15–19].
The oncomiR miR-17-5p is significantly up-regulated in mesenchymal MDA-MB-231
TNBC cells compared to the noninvasive luminal MCF7 cells, and contributes to the invasive-
ness and migratory behavior of TNBC [20]. Most TNBCs are basal-like [21, 22], and transcrip-
tion profiling has suggested that most basal-like TNBC cells have molecular properties of
mesenchymal tumors [2]. Using MDA-MB-231 cells as a mesenchymal TNBC cell model, we
hypothesized that knocking down miR-17-5p might restore the expression levels of PDCD4
and PTEN tumor suppressor proteins, illustrating a route to oligonucleotide therapy of TNBC.
Materials and Methods
OncomiR Target Prediction
Three different oncomiR target prediction algorithms, rna22, TargetScan, and Miranda [23–
26] were used to search for oncomiRs that might target PDCD4 and PTENmRNAs. These 3
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databases were chosen because of the diverse algorithms they employ to find targets. rna22
uses non-canonical seed pairing, which allows mismatches in the miRNA seed:mRNA interac-
tion. It utilizes pattern discovery to find matching sequence patterns from a miRNA:mRNA
set, then rank predicted miRNA:mRNA pairs based on free energy calculations [27]. rna22
allows G-U wobble base pairs and mismatches in the seed region. Miranda is also less stringent
about seed matching by allowing G-U wobble base pairs. Although it considers matching
sequences along the entire miRNA:mRNA pair, the final prediction favors matching in the
seed region. TargetScan relies heavily on conservation of 3’UTR interactions, followed by fully
complementary seed regions that are conserved. It does not allow mismatches or G-U wobble
base pairs, although it does consider 3’ compensatory regions.
Cell Line and Cell Culture
The human mesenchymal TNBC cell line MDA-MB-231 was obtained from American Type
Culture Collection (ATCC). MDA-MB-231 cells were characterized as basal B subtype TNBC,
with mesenchymal features that allow them to migrate readily and degrades their ability to
adhere and polarize [28]. MDA-MB-231 cells were maintained in L-15 medium (ATCC) con-
taining 10% fetal bovine serum (FBS) and 100 U/mL of penicillin/streptomycin (Invitrogen) in
a humidified incubator at 37°C without added CO2.
Knockdown Oligonucleotides
Antisense DNA-LNA chimeras were acquired from Exiqon to knock down miR17-5p (5’-
dACCTGCACTGTAAGCACTTTG-3’), miR17-3p (5’-dTACAAGTGCCTTCACTGCAG-3’),
and miR-21-5p (5’-dCAACATCAGTCTGATAAGCT-3’). Comparison of calculated pure
DNAmasses with manufacturer’s reported masses for anti-miR-17-5p (MW = 6619.3 Da),
anti-miR-17-3p (MW = 6287.1 Da), and anti-miR-21 (MW = 6337.2 Da), implied ~7 LNA res-
idues, probably at the 3’ terminus.
Mfold Energy Calculation and Structural Prediction of oncomiR:mRNA
duplexes
Gibbs free energies (folding energy ΔG°s) were calculated using Mfold [29] at http://mfold.rna.
albany.edu/?q=mfold. Since Mfold only allows a single sequence input, a linker sequence (5’-
GCGGGGACGC-3’) was inserted between each oncomiR:mRNA pair [30].
Molecular Dynamics Structural Prediction of oncomiR:mRNA duplexes
Theoretical structures of duplexes were simulated in explicit water, 100 mMNaCl, pH 7.0, at
300°K, with Amber 12 using the ff99SB force field [31, 32] as before [33, 34].
Antisense DNA-LNA treatment
1.5×105 MDA-MB-231 cells were seeded in 6-well plates in complete medium without antibi-
otics the day before transfection. Antisense DNA-LNA chimeras (Exiqon) were transfected
into MDA-MB-231 cells with 5 μg Lipofectamine 2000 (Invitrogen) at a final oligonucleotide
concentration of 50 nM for 6 hours at 37°C in Opti-MEM (Invitrogen) under 5% CO2, accord-
ing to the manufacturer’s protocol. At the end of transfection, cells were washed, then incu-
bated in complete growth medium for another 12 to 48 hours before harvesting.
miR-17-5p Passenger Strand Activity
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miRNAmimic treatment
1.5×105 MDA-MB-231 cells were seeded in 6-well plates in complete medium without antibi-
otics the day before transfection. Either miR-17-5p mimic or miR-17-3p mimic (Life Technol-
ogies) were transfected into MDA-MB-231 cells with 5 μg Lipofectamine 2000 (Invitrogen) at a
final oligonucleotide concentration of 50 nM for 6 hours at 37°C in Opti-MEM (Invitrogen)
under 5% CO2, according to the manufacturer’s protocol. At the end of transfection, cells were
washed, then incubated in complete growth medium for another 48 hours before harvesting.
Real-Time Quantitative PCR
Total RNA fromMDA-MB-231 cells was extracted using a mirVana miRNA isolation kit (Life
Technologies) according to the manufacturer’s protocol. For qPCR of miRNAs, 10 ng of puri-
fied total RNA were reverse transcribed with a TaqMan miRNA reverse transcription kit
(#4366597, Life Technologies). qPCR of miRNAs was performed with a miRNA Gene Expres-
sion Assay (Life Technologies) on a 7500 Fast Real-Time PCR System (Life Technologies).
Primers specific for miR-17 (Assay ID 002308), miR-21 (Assay ID 000397) and internal control
RNA U6 (Assay ID 001973) for both reverse transcription and qPCR were obtained from
Applied Biosystems. The average absolute values of triplicate samples for the same miRNA
were calculated and normalized to U6 RNA, measured by the comparative Ct (2-ΔΔCt) method
[35].
For qPCR of tumor suppressor mRNAs, 500 ng of purified total RNA were reverse tran-
scribed with a High Capacity cDNA Reverse Transcription Kit (Life Technologies,
cat#4368814). qPCR of mRNAs was performed using a FastStart Essential DNA Green Master
(Roche, cat#06402712001) on a LightCycler1 96 system (Roche) with the following primers to
detect transcripts: GAPDH forward primer (5’-dTCCCTCCAAAATCAAGTGGGG-3’),
GAPDH reverse primer (5’-dGCAAATGAGCCCCAGCCTTC-3’); PDCD4 forward primer
(5’-dGGGAAGGTTGCTGGATAGGC-3’), PDCD4 reverse primer (5’-dCTCCTGCAC-
CACCTTTCTTTG-3’); PTEN forward primer (5’-dGGACCAGAGACAAAAAGGGAGT-3’),
PTEN reverse primer (5’-dCCAGATGATTCTTTAACAGGTAGC-3’). The average of tripli-
cate samples for the same mRNA was calculated and normalized to the internal control gene
GAPDH, by the comparative Ct (2-ΔΔCt) method [35].
Western Blots
Cells were trypsinized and harvested with 1×PBS, then lysed in cell lysis buffer (Invitrogen)
with protease inhibitor cocktail (P-2714, Sigma). Lysate protein concentrations were quantified
by the Bradford Assay (Bio-Rad). Lysate aliquots containing 30 μg protein were separated on
NuPAGE 4–12% Bis-Tris gels (Invitrogen), transferred to PVDF membranes, blocked with
blocking buffer, and incubated with antibodies against PDCD4 protein (ab80590, Abcam),
PTEN protein (9552S, Cell Signaling), and β-actin (AM4302, Ambion), followed by incubation
with secondary antibodies labeled with horseradish peroxidase (Invitrogen). The resulting pro-
tein bands were imaged by luminescence using a SuperSignal West Femto Chemiluminescent
Substrate (Thermo Scientific), on a Kodak Image Station 2000R, and analyzed with Molecular
Imaging Software version 5.0.2.30 (Carestream).
3’UTR construct cloning
Luciferase constructs containing all predicted binding sites for miR-17-5p or miR-17-3p from
the 3’UTRs of PDCD4 or PTENmRNAs were constructed using a pMir-Report luciferase
reporter vector (AM5795, Ambion). To create the luciferase constructs containing the entire
miR-17-5p Passenger Strand Activity
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3’UTR of PDCD4smRNA, we PCR amplified the fragment from genomic DNA of MDA-MB-
231 cells using forward primer (5’–GCAACTAGTAAGCGAAGGAGATGGAGGTC– 3’),
reverse primer (5’–AAACGTTGCCCAAACGAGAGCAAT– 3’), and Phusion High-Fidelity
PCR Kit (F-553S, Thermo Scientific) following the manufacturer’s protocol. The amplified
PCR product was inserted into the pMir-Report luciferase vector between the SpeI and PmeI
restriction sites.
To generate luciferase constructs containing individual predicted 3’UTR binding sites, we
purchased the DNA sequence of each binding site, along with its flanking sequence region, as
sense and antisense primers (Fisher Scientific). The primers were then annealed and cloned
into the pMir-Report luciferase vector between the SpeI and HindIII restriction sites. The
sequence of each primer used to generate 3’UTR fragments for cloning is shown in S1 Fig.
Luciferase assay
8×104 MDA-MB-231 cells were seeded in 24-well plates in complete medium without antibiot-
ics the day before transfection. Cells were transfected with 400 ng of each of the reporter con-
structs, 100 ng of pRL-TK Renilla luciferase internal control vector (E2241, Promega), and
with either miR-17-5p mimic or miR-17-3p mimic using Lipofectamine 2000 (Invitrogen,
CA). In parallel, transfections without the mimics were performed. After 24 hours, cells were
lysed and 50 μL of each lysate was transferred to 96-well plates. Dual-Glo reporter assays were
performed according to the manufacturer’s protocol (E2920, Promega). Luminescence inten-
sity for each sample was measured with a Veritas Microplate Luminometer (Turner BioSys-
tems), and each value from pMir-Report firefly luciferase was normalized by pRK-TK Renilla
luciferase.
Statistical Analysis
All experimental measurements were performed independently at least three times. Signifi-
cance was assessed by Student’s t-test.
Results
PDCD4mRNA is a potential target for miR-17-5p
Using rna22, TargetScan and miRanda, we searched for oncomiR targets in PDCD4 and PTEN
mRNAs. rna22 identified miR-17-5p as a potential gene regulator through its interaction with
one binding site in the 3’UTR of PDCD4mRNA (Fig 1). Although rna22 is the only algorithm
that predicted a binding site for miR-17-5p in the 3’UTR of PDCD4mRNA, the predicted 23
bp oncomiR:mRNA duplex is stable, containing 17 complementary basepairs and an Mfold
predicted folding energy ΔG° of -24.5 kcal/mol at 37°C (Fig 1).
DNA-LNA chimeras knocked down oncomiRs. However, PDCD4 and
PTEN protein levels were unexpectedly decreased
To elucidate the effect of miR-17-5p on PDCD4 or PTEN, endogenous miR-17-5p was knocked
down using a commercially available DNA-LNA inhibitor. Anti-miR-17-5p DNA-LNA chi-
mera transfected into MDA-MB-231 TNBC cells knocked down miR-17-5p by 99±0.01% after
12 hr (Fig 2A). To evaluate whether miR-17-5p had any effect on the expression level of
PDCD4 protein, we analyzed protein levels 48 hr after transfection. Surprisingly, the PDCD4
protein level was down-regulated by 1.8±0.3 fold, instead of being up-regulated as expected fol-
lowing miR-17-5p knockdown (Fig 3C).
miR-17-5p Passenger Strand Activity
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To determine whether the complementary DNA-LNA chimeras were working as predicted,
we examined another direct target of miR-17-5p, PTENmRNA [14]. Both miRanda and TargetS-
can predicted one binding site for miR-17-5p in the 3’UTR of PTENmRNA (Fig 1). Surprisingly,
we found that knocking downmiR-17-5p decreased PTEN protein level by 1.8±0.3 fold (Fig 3C).
This result conflicted with the expectation that miR-17-5p target expression would increase
when miR-17-5p was knocked down. These results implied that mature miR-17-5p is a gene reg-
ulator of PDCD4 and PTENmRNA translation. However, anti-miR-17-5p resulted in down-reg-
ulation of both PDCD4 and PTENmRNA translation, rather than stimulation.
miR-17-3p passenger strand is a potential inhibitor of PDCD4 and PTEN
mRNAs, as well as miR-17-5p
To understand the unexpected results in Fig 3B, we examined miR-17 in miRBase. In the pre-
miRNA, miR-17-5p was predicted to hybridize with its passenger strand miR-17-3p to form a
Fig 2. Treatment with complementary DNA-LNA chimeras knocked down endogenousmiRNAs in MDA-MB-231 TNBC cells. A: qPCR of miR-17-5p
12 hr and 48 hr post-transfection with anti-miR-17-5p. B: qPCR of miR-21-5p 12 hr and 48 hr post-transfection with anti-miR-21-5p. Results represent
absolute values of miRNA/internal control U6 normalized to mock transfected. Values are the average of three measurements ±.
doi:10.1371/journal.pone.0142574.g002
Fig 1. Predicted miR-17-5p guide strand binding sites in the 3'UTR of PDCD4 and PTENmRNAs. aThe
potential oncomiR:mRNA binding sites were identified by rna22, Targetscan, or miRanda. bTop strand is
mRNA (5'➔ 3') and the bottom strand is oncomiR (3'➔ 5'). cCalculated at http://mfold.rna.albany.edu/?q=
mfold.
doi:10.1371/journal.pone.0142574.g001
miR-17-5p Passenger Strand Activity
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hairpin (Fig 3A). Most of the miR-17-3p is fully complementary to its guide strand miR-17-5p.
Since anti-miR-17-5p is fully complementary to miR-17-5p, its sequence is highly homologous
to miR-17-3p (Fig 3B). Therefore, we speculated that anti-miR-17-5p DNA-LNA chimera
could act as a miR-17-3p mimic, binding to miR-17-3p target sites in the 3’UTR of PDCD4 and
PTENmRNAs.
Fig 3. miR-17-3p is a potential regulator of PDCD4 protein level and competes with miR-17-5p for inhibition of PDCD4 and PTENmRNAs.miR-21-
5p guide strand regulates PDCD4 protein level without competing with its passenger strand miR-21-3p. A: Mirbase search of miR-17-3p, forming the lower
arm of the miR-17 pre-miRNA hairpin.B: Homologous sequences between miR-17-5p and miR-17-3p are highlighted in yellow. C: PDCD4 and PTEN protein
Western blots at 48 hr post transfection with anti-miR-17-5p.D: PDCD4 and PTEN protein Western blots at 48 hr post transfection with anti-miR-17-3p. E:
PDCD4 protein Western blot at 48 hr post transfection with anti-miR-21. β-actin was used as loading control. Values are the average of three blots ± s.d. after
normalization to β-actin and to control/treatment group. Each blot was subjected to gamma setting adjustments.
doi:10.1371/journal.pone.0142574.g003
miR-17-5p Passenger Strand Activity
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To test this hypothesis, rna22, TargetScan and miRanda were used to identify potential
binding sites for miR-17-3p in the 3’UTR of PDCD4 and PTEN. Four potential binding sites
for miR-17-3p were noted in the PDCD4 3’UTR (Fig 4), while the PTEN 3’UTR had six (Fig 5).
For each predicted oncomiR:mRNA interaction, the CUGCA motif within the seed region of
miR-17-3p is complementary to the corresponding 3’UTR binding sites. This same sequence
motif exists in anti-miR-17-5p (Fig 3A). Thus, considering seed pairing as one of the important
factors in miRNA:target recognition, all of the miR-17-3p target sites in the 3’UTRs of PDCD4
and PTEN could be putative binding sites for anti-miR-17-5p.
OncomiR:mRNA duplex structures are stable
Based on the hypothesis that anti-miR-17-5p mimicked miR-17-3p, the interaction between
anti-miR-17-5p and miR-17-3p binding sites in the 3’UTR should be stable. We tested our the-
ory by folding anti-miR-17-5p onto miR-17-3p target sites in the PDCD4 and PTEN 3’UTRs.
Since Mfold only allows a linear sequence to be the input, we connected the two sequences
with a sequence linker (5’-GCGGGGACGC-3’) [30].
As a result, all the anti-miR-17-5p:mRNA pairs were successfully folded with a slightly
lower folding energy compared to miR-17-3p:mRNA predictions by rna22 and miRanda (Figs
4–7). However, the lowered folding energy could be compensated by the LNA residues within
anti-miR-17-5p, since LNA:RNA duplexes are highly stable [36]. Similarly, anti-miR-17-3p
could mimic miR-17-5p and bind to all of the miR-17-5p target sites on the 3’UTR of PDCD4
and PTENmRNAs (Fig 3A, Fig 8).
OncomiR:mRNA duplex structures occupy A-form helices
Our molecular dynamics calculations predicted stable A-form duplexes for all passenger strand:
mRNA targets, as well as for guide strands, despite the mismatches and bulges that appear so
Fig 4. Predicted miR-17-3p passenger strand binding sites in the 3'UTR of PDCD4mRNA. aThe
potential oncomiR:mRNA binding sites were identified by rna22, Targetscan, or miRanda. bTop strand is
mRNA (5'➔ 3') and the bottom strand is oncomiR (3'➔ 5'). cCalculated at http://mfold.rna.albany.edu/?q=
mfold.
doi:10.1371/journal.pone.0142574.g004
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distorted in the Mfold presentation. The example of miR-17-3p bound to a PTEN 3’UTR site
(Fig 9) illustrates the realization that miRNA:mRNA: duplexes could be accommodated in the
substrate groove of Ago2, in agreement with an earlier simulation of an 11mer duplex bound to
Thermus thermophilusAgo [37]. An animated mpg file showing 25 nsec of simulation at 300°K
in explicit water with 100 mMNaCl, at pH 7.0, can be viewed in S1 Movie. These results indi-
cated that miRNA inhibitors composed of LNA-DNA could also be bound to Ago when they
form duplexes with target miRNAs, since LNA:RNA will pre-organize the helices in A-form.
Inhibition of the miR-17-3p passenger strand maintained PDCD4 and
PTEN protein levels
To determine if the passenger strand was involved in the contradictory results above, we
knocked down endogenous miR-17-3p with anti-miR-17-3p and analyzed PDCD4 and PTEN
protein expression levels. In contrast to miR-17-5p knockdown (Fig 3C), miR-17-3p knock-
down showed no significant changes in PDCD4 or PTEN protein levels (Fig 3D). The main-
tained protein levels of PDCD4 and PTEN could be a comprehensive outcome of both miR-
17-5p and miR-17-3p binding to the PDCD4 and PTEN 3’UTRs. The static result is plausible,
because there are more potential binding sites for miR-17-3p on the 3’UTR of PDCD4 and
Fig 5. Predicted miR-17-3p passenger strand binding sites in the 3'UTR of PTENmRNA. aThe potential
oncomiR:mRNA binding sites were identified by rna22, Targetscan, or miRanda. bTop strand is mRNA (5'➔
3') and the bottom strand is oncomiR (3'➔ 5'). cCalculated at http://mfold.rna.albany.edu/?q=mfold.
doi:10.1371/journal.pone.0142574.g005
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PTENmRNAs compared to that of miR-17-5p (Fig 4 and Fig 5), although anti-miR-17-3p
could act as a miR-17-5p mimic (Fig 3A and Fig 8). In addition, qPCR results showed that the
endogenous level of miR-17-5p was about ninety times higher than miR-17-3p in MDA-MB-
231 cells (S2A Fig). Thus, knocking down the low level of miR-17-3p passenger strand might
not have a noticeable effect.
miR-21-5p guide strand knockdown elevated PDCD4 protein level
To further test our hypothesis, we treated MDA-MB-231 cells with anti-miR-21-5p to knock
downmiR-21-5p, an established regulator of PDCD4 [38], then measured the effect on PDCD4
protein. rna22, TargetScan, and miRanda predicted that miR-21-5p has two binding sites in the
3’UTR of PDCD4, while its passenger strand miR-21-3p has no putative binding sites, unlike miR-
17-3p (Fig 10). Anti-miR-21-5p knocked downmiR-21-5p by 96±0.15% (Fig 2B), and increased
PDCD4 protein expression by 1.4±0.3 fold (Fig 3E). Consistent with the predicted absence of a
miR-21-3p site on PDCD4mRNA, anti-miR-21-5p did not down-regulate PDCD4 protein level.
miR-17-3p knockdown increased the steady state level of PDCD4
mRNA
To investigate whether anti-miR DNA-LNA chimeras influence mRNAs at the transcriptional
level, we measured PDCD4mRNA levels by qPCR 12 hr and 48 hr post-transfection. At 12 hr
and 48 hr, neither miR-17-5p knockdown nor miR-17-3p knockdown correlated with any sig-
nificant change in PDCD4mRNA compared to control (Fig 11A and 11B), while miR-21-5p
knockdown significantly increased PDCD4mRNA by 33±9.6% at 12 hr and 17±3.3% at 48 hr
(Fig 11A). However, PDCD4mRNA showed a 25±1.7% increase in its steady state with anti-
miR-17-3p relative to anti-miR-17-5p treatment from 12 hr to 48 hr (Fig 11C).
Fig 6. Predicted anti-miR-17-5p binding sites in the 3'UTR of PDCD4mRNA as amimic of miR-17-3p
passenger strand. aThe potential oncomiR:mRNA binding sites were identified by rna22, Targetscan, or
miRanda. bTop strand is mRNA (5'➔ 3') and the bottom strand is oncomiR (3'➔ 5'). cCalculated at http://
mfold.rna.albany.edu/?q=mfold.
doi:10.1371/journal.pone.0142574.g006
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miR-17-5p knockdown decreased PTENmRNA level, while miR-17-3p
knockdown increased the steady state level of PTENmRNA
A similar phenomenon was observed with PTENmRNA. At 12 hr and 48 hr after anti-miR-
17-5p transfection, PTENmRNA was significantly decreased by 15±4% at 12 hr and 22±6% at
48 hr, while no significant change was seen with anti-miR-17-3p, compared to control (Fig
11B). Moreover, the steady state of PTENmRNA from 12 hr to 48 hr showed a significant
increase (35±6%) with anti-miR-17-3p, compared with anti-miR-17-5p (Fig 11D).
Both miR-17-5p and miR-17-3p directly affect the translation of PDCD4
and PTENmRNAs
To test the hypothesis that the translation of PDCD4 and PTENmRNAs are directly inhibited
by miR-17-5p and miR-17-3p, we transfected MDA-MB-231 cells with either miR-17-5p
mimic or miR-17-3p mimic, and measured the protein levels of PDCD4 and PTEN 48 hr post-
transfection. Exogenous miR-17-5p mimic lowered both PDCD4 and PTEN protein levels
Fig 7. Predicted anti-miR-17-5p binding sites in the 3'UTR of PTENmRNA as amimic of miR-17-3p
passenger strand. aThe potential oncomiR:mRNA binding sites were identified by rna22, Targetscan, or
miRanda. bTop strand is mRNA (5'➔ 3') and the bottom strand is oncomiR (3'➔ 5'). cCalculated at http://
mfold.rna.albany.edu/?q=mfold.
doi:10.1371/journal.pone.0142574.g007
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(Fig 12A). Transfection with miR-17-3p mimic lowered PTEN protein level, but not PDCD4
protein level (Fig 12A). This could be explained by the low endogenous expression level of
miR-17-3p passenger strand compared to miR-17-5p guide strand (S2A Fig). Indeed, qPCR
showed that transfection with miR-17-5p guide strand mimic increased the measured level of
miR-17-5p by over 800-fold (S2B Fig), while transfection with miR-17-3p passenger strand
mimic only increased its measured level by 100-fold (S2C Fig).
Both miR-17-5p and miR-17-3p directly interact with the 3’UTR of
PDCD4 and PTENmRNAs
To study the mechanism of post-transcriptional regulation of PDCD4 and PTENmRNAs by
miR-17-5p and miR-17-3p, we cloned individual binding sites for miR-17-5p or miR-17-3p
(Fig 1, Fig 3 and Fig 4) in the 3’UTR of PDCD4 or PTENmRNAs into luciferase reporter vec-
tors right after the luciferase gene. Since PDCD4 has not been reported to be a target for miR-
17-5p or miR-17-3p, we also cloned the whole 3’UTR of PDCD4mRNA into the luciferase
reporter vector. The resulting luciferase constructs were expected to express luciferase mRNAs
Fig 8. Predicted anti-miR-17-3p binding sites in the 3'UTR of PDCD4 and PTENmRNAs as amimic of
miR-17-5p passenger strand. aThe potential oncomiR:mRNA binding sites were identified by rna22,
Targetscan, or miRanda. bTop strand is mRNA (5'➔ 3') and the bottom strand is oncomiR (3'➔ 5').
cCalculated at http://mfold.rna.albany.edu/?q=mfold.
doi:10.1371/journal.pone.0142574.g008
Fig 9. Minimum energy structure predicted with Amber 12 for miR-17-3p:PTENmRNA duplex in
explicit H2O with 100 mMNaCl, pH 7.0, at 300°K.
doi:10.1371/journal.pone.0142574.g009
miR-17-5p Passenger Strand Activity
PLOS ONE | DOI:10.1371/journal.pone.0142574 December 2, 2015 12 / 20
containing the miRNA binding sites as their 3’UTR. MDA-MB-231 cells were co-transfected
with each luciferase construct, miR-17-5p or miR-17-3p mimic, and a pRL-TK Renilla lucifer-
ase vector served as a transfection efficiency control. In parallel, the same transfection was also
done without the addition of mimic for each luciferase construct to obtain the baseline lucifer-
ase signal. The luciferase light units from each construct were first normalized to that of Renilla
luciferase vector, then further normalized to the corresponding baseline signal without the
mimic. The vector containing the luciferase gene, and the restriction sites in the luciferase
3’UTR, was used as a negative control.
Compared to vector control, miR-17-5p mimic lowered the luciferase activity of both pre-
dicted PDCD4 binding sites and the entire PDCD4 3’UTR (Fig 12B), suggesting that miR-17-
5p can directly target PDCD4mRNA. Similarly, miR-17-5p mimic lowered the luciferase activ-
ity of the vectors containing the binding sites from the PTEN 3’UTR (Fig 12C). Exogenous
miR-17-3p mimic lowered luciferase activities from vector constructs harboring each of the
four predicted binding sites, as well as the construct containing the whole 3’UTR of PDCD4
mRNA (Fig 12D), indicating that both miR-17-5p guide strand and miR-17-3p passenger
strand could directly target PDCD4mRNA. miR-17-3p mimic lowered luciferase activities of
four out of six predicted binding sites in the 3’UTR of PTENmRNA (Fig 12E).
Anti-miR-17-5p DNA-LNA inhibitors act as miR-17-3p mimics, and
reduced the translation of PDCD4 and PTENmRNAs
To investigate whether anti-miR-17-5p DNA-LNA could mimic miR-17-3p by binding to the
predicted sites for miR-17-3p in the 3’UTR of PDCD4 and PTEN, we carried out the luciferase
experiments by co-transfecting MDA-MB-231 cells with luciferase constructs and anti-miR-
17-5p as described above. Compared to vector control, anti-miR-17-5p lowered the activity of
luciferase vectors containing two out of four PDCD4 3’UTR binding sites predicted for miR-
17-3p (Fig 13A). However, it did not affect luciferase activity from the vector containing the
entire 3’UTR of PDCD4mRNA (Fig 13A). Since the whole PDCD4 3’UTR is much longer than
the individual binding sites, the secondary and tertiary structure of the entire 3’UTR might be
changed after being cloned after the luciferase gene. Anti-miR-17-5p also lowered luciferase
activities of constructs harboring four out of six PTEN 3’UTR binding sites predicted for miR-
17-3p (Fig 13B). These results implied that artificial anti-miR-17-5p DNA-LNA against miR-
Fig 10. PredictedmiR-21-5p guide strand binding sites in the 3'UTR of PDCD4mRNA. aThe potential
oncomiR:mRNA binding sites were identified by rna22, Targetscan, or miRanda. bTop strand is mRNA (5'➔
3') and the bottom strand is oncomiR (3'➔ 5'). cCalculated at http://mfold.rna.albany.edu/?q=mfold.
doi:10.1371/journal.pone.0142574.g010
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17-5p guide strand could exert functions of an miRNA by mimicking the passenger strand of
miR-17-5p, and could interact with some of the miR-17-3p binding sites in the 3’UTR of
PDCD4 and PTENmRNAs.
Discussion
In our study, we discovered that in MDA-MB-231 TNBC cells, anti-miR-17-5p DNA-LNA
chimera knocked down endogenous miR-17-5p, but surprisingly decreased the protein levels
coded by their potential targets PDCD4 and PTENmRNAs, rather than elevating them. In con-
trast, anti-miR-17-3p knocked down endogenous miR-17-3p, but maintained PDCD4 and
Fig 11. Effect of complementary DNA-LNA chimeras on the PDCD4 and PTENmRNA levels in MDA-MB-231 cells. A: qPCR of PDCD4mRNA at 12 hr
and 48 hr after transfection.B: qPCR of PTENmRNA at 12 hr and 48 hr after transfection.C: Relative expression of PDCD4mRNA from 12 hr to 48 hr after
transfection with anti-miR-17-5p and anti-miR-17-3p. D: Relative expression of PTENmRNA from 12 hr to 48 hr after transfection with anti-miR-17-5p and
anti-miR-17-3p. Results represent absolute values of miRNA/internal control geneGAPDH normalized to mock transfected. Values are the average of three
measurements ± s.d. * indicates p<0.05, ** indicates p<0.01.
doi:10.1371/journal.pone.0142574.g011
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PTEN protein expression (Fig 3C). We ascribe this result to limited binding sites for the miR-
17-5p guide strand relative to the miR-17-3p passenger strand.
Through mRNA sequence analysis, we found four putative binding sites for miR-17-3p rela-
tive to one for miR-17-5p in the 3’UTR of PDCD4mRNA. Thus, while the anti-miR-17-5p
could silence miR-17-5p and theoretically alleviate the translational inhibition of PDCD4
mRNA, as a miR-17-3p mimic it apparently repressed the translation of PDCD4mRNA by
binding to multiple 3’UTR target sites for miR-17-3p (Fig 13 and Fig 14). Although the endoge-
nous passenger strand miR-17-3p had only modest effects in modulating PDCD4 and PTEN
post-transcriptionally (Fig 3D and Fig 12A), the passenger strand mimicking anti-miR-17-5p
could target PDCD4mRNAmore effectively than the miR-17-5p guide strand. This phenome-
non could be explained by the excess amount of highly stable anti-miR inhibitors introduced
into the cells, which could be associated with Ago, and form strong interactions with the
Fig 12. Both miR-17-5p andmiR-17-3p can directly modulate the translation of PDCD4 and PTEN. A: PDCD4 and PTEN proteinWestern blots at 48 hr
post transfection with miR-17-5p mimic or miR-17-3p mimic. β-actin was used as loading control. Values are the average of three blots ± s.d. after
normalization to β-actin and to control/treatment group. Each blot was subjected to gamma setting adjustments. B—E: Luciferase activity after co-
transfecting MDA-MB-231 cells with indicated luciferase reporter constructs in the presence or absence of miRNAmimic. All luciferase signals from pMir-
report firefly luciferase vectors are normalized to signals from pRL-TK Renilla luciferase vector. The ratio of normalized signal in the presence of mimic to
signal in the absence of mimic for each construct is then calculated. The pMir-report luciferase vector is used as negative control. Results represent fold
changes of the above ratio relative to vector control. Values are the average of at least three measurements ± s.e.m * indicates p<0.05, ** indicates p<0.01.
doi:10.1371/journal.pone.0142574.g012
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targeting miRNAs. Moreover, the anti-miR inhibitors could be selected by Ago to perform
functions of a miRNA due to their pre-organized A-form structure, and could target mRNAs
with great side effects through binding to multiple 3’UTR sites.
Fig 13. Anti-miR-17-5p DNA-LNA can directly modulate the translation of PDCD4 and PTENmRNAs through interactions with multiple binding
sites from the 3’UTR. Luciferase activity after co-transfecting MDA-MB-231 cells with indicated luciferase reporter constructs in the presence or absence of
DNA-LNA inhibitor. A: PDCD4. B: PTEN. All luciferase signals from pMir-report are normalized to signals from pRL-TK Renilla luciferase vector. The ratio of
normalized signal in the presence of DNA-LNA inhibitor to signal in the absence of inhibitor for each construct is then calculated. The pMir-report luciferase
vector was used as a negative control. Results represent fold changes of the above ratio relative to vector control. Values are the average of at least three
measurements ± s.e.m * indicates p<0.05, ** indicates p<0.01.
doi:10.1371/journal.pone.0142574.g013
Fig 14. Schematic view of competition between anti-miR-17-5p andmiR-17-5p for inhibition of PDCD4
mRNA.
doi:10.1371/journal.pone.0142574.g014
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On the other hand, anti-miR-21-5p did not constitute a passenger strand mimic that com-
petes with the guide strand for binding to target mRNAs. Thus, knocking down miR-21-5p
consistently increased PDCD4 protein levels (Fig 3E) and PDCD4mRNA levels (Fig 11A) at 12
hr and 48 hr after transfection by relieving translational inhibition of PDCD4mRNA by miR-
21-5p (Fig 14).
These results suggest that a miRNA inhibitor designed to bind to the mature guide strand
could potentially constitute a mimic of the passenger strand. As a result, an oncomiR guide
strand inhibitor could fail if passenger strand binding sites exist in the 3’UTR of target
mRNAs. This effect was not apparent in an earlier study in lymphocytes that utilized a lucifer-
ase vector containing only a fragment of the PTEN 3’UTR bearing the single miR-17-5p target
[14].
Recent literature has reported some examples of cancer cells with substantial activity exhib-
ited by passenger strand species, including mRNA regulatory activities [39–44]. For example,
in hepatocellular carcinoma, miR-17-5p reduced the translation of PTENmRNA, while miR-
17-3p directly targeted vimentin mRNA [45]. As a result, miR-17-5p and miR-17-3p coopera-
tively contribute to the development of hepatocellular carcinoma. The same investigators
reported that both the guide strand and the passenger strand of miR-17 targeted sites in
TIMP3mRNA in prostate cancer cells, thus promoting proliferation and invasion [46].
Those observations in hepatocellular carcinoma and prostate cancer cells, and our own in
TNBC cells, contradict the conventional model in which the passenger strands of miRNAs are
dissociated and degraded.
Thus, when studying an oncomiR guide strand, one must consider that its passenger strand
could also be functional. Furthermore, the expression patterns of passenger strand species vs.
guide strand species should also be characterized at various cell cycle stages, since the two
oncomiR strands are not always expressed equally as cell growth progresses [47, 48]. Finally,
when combining the effect of the two oncomiR strands, different scenarios of consequences
must be investigated since the guide strand and the passenger strand miRNAs could theoreti-
cally work in synergy, in opposing fashion, or independently. Clearly, oncomiRs regulate genes
via a fine-tuning process.
Based on the findings that both oncomiR strands could be functional, precaution must be
taken when designing oncomiR knockdown sequences as potential therapeutic or diagnostic
agents, since both the guide strand and the passenger strand of an oncomiR might target the
same transcript. For research and therapeutic purposes, developing oncomiR inhibitors or
mimics that modulate the functionality of either the guide strand or the passenger strand spe-
cifically and independently is valuable. Inhibitors specific to one strand or the other will dimin-
ish contradictory side effects associated with mimicking the passenger strand.
For future investigations, the activity of passenger strand species from other oncomiRs
should also be explored in multiple TNBC cell models. In this study, only two genes were
found to be regulated by miR-17 passenger strand. As each oncomiR could target hundreds of
gene transcripts, one could expect a comparable number of mRNA targets for oncomiR pas-
senger strand relative to their guide strand.
To characterize the functionality of oncomiR passenger strand species, a global RNA expres-
sion analysis will be essential in combination with oncomiR target prediction algorithms and
molecular dynamics calculations of complex stability. Gene expression profiling in concor-
dance with oncomiR guide and passenger strand expression will provide us with more powerful
insight into the purpose of active passenger strand species.
miR-17-5p Passenger Strand Activity
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